Dana-Farber Cancer Institute operates as a Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapy. The Cellular Therapies Program at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) builds on stem cell transplantation, ensuring a robust platform for developing innovative therapies. Cells are processed either at an external commercial facility or within the Connell and O'Reilly Families Cell Manipulation Core Facility. The centre is engaged in the primary cell manufacturing of genetically engineered products, positioning itself as a significant player in the pharmaceutical industry.

Services include:
- Cellular therapy manufacturing
- Gene therapy manufacturing
- Stem cell transplantation support
- Processing of genetically engineered products

Dana-Farber Cancer Institute remains committed to advancing the field of cellular therapies and offers a range of services aimed at providing cutting-edge treatments for patients. For more information, please visit dana-farber.org.